Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinicians(Electronic Edition) ›› 2026, Vol. 20 ›› Issue (06): 479-486. doi: 10.3877/cma.j.issn.1674-0785.2026.06.009

• Review • Previous Articles    

Immune combination strategies in conversion therapy for microsatellite stable/mismatch repair proficient colorectal cancer

Jianfeng Zhang1, Zeming Zhao2, Xueliang Wu3, Hongqing Ma1, Guiying Wang1,2,†()   

  1. 1 The Second Department of Surgery of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050001, China
    2 Department of General Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
    3 The First Hospital Affiliated to Hebei North University, Zhangjiakou 075132, China
  • Received:2026-05-04 Online:2026-06-30 Published:2026-11-16
  • Contact: Guiying Wang

Abstract:

Colorectal cancer is one of the most common malignancies in China, with approximately 80%-85% of cases classified as microsatellite stable/mismatch repair proficient (MSS/pMMR). This subtype exhibits a low response rate to immune checkpoint inhibitor (ICI) monotherapy, posing a major challenge in the field of CRC immunotherapeutic conversion. Recent advances in understanding the conversion mechanisms of the tumor immune microenvironment from a "cold" to a "hot" state have facilitated the development of ICI-based combination strategies. These include regimens that incorporate targeted therapies, chemotherapy, or anti-angiogenic agents, which have shown promise in overcoming immune resistance in clinical studies and offer new avenues for converting MSS/pMMR CRC. From a clinical perspective with an emphasis on surgical treatment, this article systematically reviews the mechanisms and clinical progress of various ICI combination strategies. It discusses key scientific issues such as efficacy evaluation, optimal timing of surgery, and perioperative safety management, while also exploring future directions for precision medicine and multidisciplinary team collaboration. The review aims to provide valuable insights for both clinical practice and research in the conversion therapy of MSS/pMMR colorectal cancer.

Key words: MSS/pMMR colorectal cancer, Tumor immune microenvironment, Conversion therapy, Immune combination therapy

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinicians(Electronic Edition), All Rights Reserved.
Tel: 010-57830845 E-mail: zhlcyszz@cma.org.cn
Powered by Beijing Magtech Co. Ltd